Loading...
Multiple randomized trials have provided compelling evidence of an improvement in overall survival for patients with hormone-sensitive metastatic prostate cancer managed with androgen deprivation therapy (ADT) plus intensification with agents including abiraterone, enzalutamide, apalutamide, darolutamide, and docetaxel. Despite this, most patients progress to a castration-resistant disease state, which is currently incurable. The development of novel hormonal agents that can overcome the myriad resistance pathways remains an important area of investigation.
In an industry-sponsored phase 1/2 trial, investigators evaluated ODM-208, a novel inhibitor of cytochrome P450 11A, in patients with progressive metastatic castration-resistant prostate …